{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T01:04:30Z","timestamp":1794963870227,"version":"4.9.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    In approximately one third of patients, resected head and neck squamous cell carcinoma will recur. We postulated that the induction of tumor neoantigen-specific T cell responses could prevent relapse. To this end, we developed TG4050, an individualized neoantigen therapeutic vaccine encoding up to 30 patient-specific predicted tumor neoantigens delivered by a Modified Vaccinia Ankara viral vector. We tested adjuvant TG4050 as single agent in a randomized phase I trial comparing treatment with TG4050 immediately after standard of care adjuvant therapy versus watchful waiting and treatment with TG4050 after recurrence (NCT04183166). The primary endpoint was safety, secondary endpoints included feasibility and efficacy, and immunogenicity was exploratory. TG4050 was well tolerated. Of 16 evaluable patients randomized the immediate treatment arm, none relapsed after a median follow-up of 30 months, while 3 of 16 relapsed in the control arm. T cell responses to vaccine neoantigens were detected in 73.3% of patients treated with TG4050 immediately, with a median of 3 neoantigens per responder. These responses were maintained throughout treatment and persisted for over one year after the last dose. Vaccine neoantigen-specific CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells had an effector phenotype, displayed high expression of cytotoxic and tissue-resident markers, were polyclonal and comprised both de novo responses and amplification of pre-existing tumor-infiltrating T cell clones. Together, these translational data are consistent with the hypothesis in which single-agent delivery of TG4050 induces long-lasting tumor neoantigen-specific cytotoxic T cell responses that can prevent tumor recurrence.\n                  <\/jats:p>","DOI":"10.1038\/s41467-026-76667-1","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:07:14Z","timestamp":1786979234000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A viral-based individualized neoantigen vaccine as adjuvant treatment in resected head and neck squamous cell carcinoma: a randomized Phase I trial"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3619-1657","authenticated-orcid":false,"given":"Christian","family":"Ottensmeier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Delord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3898-5426","authenticated-orcid":false,"given":"Ana","family":"Lalanne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Jamet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Laure","family":"Le Gac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katell","family":"Bidet Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beno\u00eet","family":"Grellier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jules","family":"Deforges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maud","family":"Brandely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Qu\u00e9m\u00e9neur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9rang\u00e8re","family":"Bastien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Tavernaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gis\u00e8le","family":"Lacoste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Schoettel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mentine","family":"Spring-Giusti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4696-7586","authenticated-orcid":false,"given":"Nathalie","family":"Silvestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Baptiste","family":"Marchand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Robin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Dochy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Ceppi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Riva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Yamagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Brattas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhide","family":"Onoguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiko","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugues","family":"Fontenelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7085-6106","authenticated-orcid":false,"given":"Mariana","family":"Eggert Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Schache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2455-8442","authenticated-orcid":false,"given":"Eliane","family":"Piaggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2185-9116","authenticated-orcid":false,"given":"Ka\u00efdre","family":"Bendjama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3161-7719","authenticated-orcid":false,"given":"Olivier","family":"Lantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9772-4686","authenticated-orcid":false,"given":"Christophe","family":"Le Tourneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"76667_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"76667_CR2","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1093\/annonc\/mdu265","volume":"25","author":"A Psyrri","year":"2014","unstructured":"Psyrri, A., Rampias, T. & Vermorken, J. B. The current and future impact of human papillomavirus on treatment of squamous cell carcinoma of the head and neck. Ann. Oncol. 25, 2101\u20132115 (2014).","journal-title":"Ann. Oncol."},{"key":"76667_CR3","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1016\/j.annonc.2020.07.011","volume":"31","author":"JP Machiels","year":"2020","unstructured":"Machiels, J. P. et al. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 31, 1462\u20131475 (2020).","journal-title":"Ann. Oncol."},{"key":"76667_CR4","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers, Version 2.2023. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/head-and-neck.pdf (2023)."},{"key":"76667_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.oraloncology.2018.11.010","volume":"88","author":"S Haque","year":"2019","unstructured":"Haque, S. et al. High-risk pathological features at the time of salvage surgery predict poor survival after definitive therapy in patients with head and neck squamous cell carcinoma. Oral. Oncol. 88, 9\u201315 (2019).","journal-title":"Oral. Oncol."},{"key":"76667_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-25291-2","volume":"12","author":"S Basyuni","year":"2022","unstructured":"Basyuni, S. et al. Value of p53 sequencing in the prognostication of head and neck cancer: a systematic review and meta-analysis. Sci. Rep. 12, 20776 (2022).","journal-title":"Sci. Rep."},{"key":"76667_CR7","doi-asserted-by":"publisher","first-page":"3818","DOI":"10.3390\/ijms23073818","volume":"23","author":"S Nair","year":"2022","unstructured":"Nair, S., Bonner, J. A. & Bredel, M. EGFR mutations in head and neck squamous cell carcinoma. Int. J. Mol. Sci. 23, 3818 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"76667_CR8","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris, R. L. et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 375, 1856\u20131867 (2016).","journal-title":"N. Engl. J. Med."},{"key":"76667_CR9","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness, B. et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 394, 1915\u20131928 (2019).","journal-title":"Lancet"},{"key":"76667_CR10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1056\/NEJMoa2415434","volume":"393","author":"R Uppaluri","year":"2025","unstructured":"Uppaluri, R. et al. Neoadjuvant and adjuvant pembrolizumab in locally advanced head and neck cancer. N. Engl. J. Med. 393, 37\u201350 (2025).","journal-title":"N. Engl. J. Med."},{"key":"76667_CR11","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/S0140-6736(25)01850-1","volume":"407","author":"J Bourhis","year":"2026","unstructured":"Bourhis, J. et al. Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trial. Lancet 407, 363\u2013374 (2026).","journal-title":"Lancet"},{"key":"76667_CR12","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41572-020-00224-3","volume":"6","author":"DE Johnson","year":"2020","unstructured":"Johnson, D. E. et al. Head and neck squamous cell carcinoma. Nat. Rev. Dis. Prim. 6, 92 (2020).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"76667_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-95718-9","volume":"11","author":"I Mito","year":"2021","unstructured":"Mito, I. et al. Comprehensive analysis of immune cell enrichment in the tumor microenvironment of head and neck squamous cell carcinoma. Sci. Rep. 11, 16134 (2021).","journal-title":"Sci. Rep."},{"key":"76667_CR14","doi-asserted-by":"publisher","first-page":"117544","DOI":"10.1016\/j.biopha.2024.117544","volume":"180","author":"M Torri","year":"2024","unstructured":"Torri, M., Sandell, A. & Al-Samadi, A. The prognostic value of tumor-infiltrating lymphocytes in head and neck squamous cell carcinoma: A systematic review and meta-analysis. Biomed. Pharmacother. 180, 117544 (2024).","journal-title":"Biomed. Pharmacother."},{"key":"76667_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-01020-6","volume":"9","author":"L Paschold","year":"2025","unstructured":"Paschold, L. et al. Inflammation and limited adaptive immunity predict worse outcomes on immunotherapy in head and neck cancer. npj Precis. Oncol. 9, 272 (2025).","journal-title":"npj Precis. Oncol."},{"key":"76667_CR16","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1007\/s00262-025-03993-6","volume":"74","author":"X Wang","year":"2025","unstructured":"Wang, X. et al. Clinical significance of peripheral T-cell repertoire in head and neck squamous cell carcinoma treated with cetuximab and nivolumab. Cancer Immunol. Immunother. 74, 142 (2025).","journal-title":"Cancer Immunol. Immunother."},{"key":"76667_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-13346-z","volume":"15","author":"J Lai","year":"2025","unstructured":"Lai, J., Huang, R. & Huang, J. Predicting head and neck cancer response to radiotherapy with a chemokine-based model. Sci. Rep. 15, 28450 (2025).","journal-title":"Sci. Rep."},{"key":"76667_CR18","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41571-024-00969-w","volume":"22","author":"M Zhao","year":"2025","unstructured":"Zhao, M. et al. T cell dynamics with neoadjuvant immunotherapy in head and neck cancer. Nat. Rev. Clin. Oncol. 22, 83\u201394 (2025).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"76667_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","volume":"8","author":"N Xie","year":"2023","unstructured":"Xie, N. et al. Neoantigens: promising targets for cancer therapy. Signal Transduct. Target. Ther. 8, 9 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"76667_CR20","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1158\/2159-8290.CD-24-0158","volume":"14","author":"JF Gainor","year":"2024","unstructured":"Gainor, J. F. et al. T-cell responses to individualized neoantigen therapy mRNA-4157 (V940) alone or in combination with pembrolizumab in the phase 1 KEYNOTE-603 study. Cancer Discov. 14, 2209\u20132223 (2024).","journal-title":"Cancer Discov."},{"key":"76667_CR21","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas, L. A. et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618, 144\u2013150 (2023).","journal-title":"Nature"},{"key":"76667_CR22","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41591-024-03334-7","volume":"31","author":"J Lopez","year":"2025","unstructured":"Lopez, J. et al. Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial. Nat. Med. 31, 152\u2013164 (2025).","journal-title":"Nat. Med."},{"key":"76667_CR23","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/s41586-025-10004-2","volume":"651","author":"U Sahin","year":"2026","unstructured":"Sahin, U. et al. Individualized mRNA vaccines evoke durable T cell immunity in adjuvant TNBC. Nature 651, 1088\u20131096 (2026).","journal-title":"Nature"},{"key":"76667_CR24","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.ccell.2022.08.003","volume":"40","author":"MM Awad","year":"2022","unstructured":"Awad, M. M. et al. Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer. Cancer Cell 40, 1010\u20131026.e11 (2022).","journal-title":"Cancer Cell"},{"key":"76667_CR25","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41586-024-08507-5","volume":"639","author":"DA Braun","year":"2025","unstructured":"Braun, D. A. et al. A neoantigen vaccine generates antitumour immunity in renal cell carcinoma. Nature 639, 474\u2013482 (2025).","journal-title":"Nature"},{"key":"76667_CR26","doi-asserted-by":"publisher","first-page":"5125","DOI":"10.1016\/j.cell.2025.06.019","volume":"188","author":"E Blass","year":"2025","unstructured":"Blass, E. et al. A multi-adjuvant personal neoantigen vaccine generates potent immunity in melanoma. Cell 188, 5125\u20135141.e27 (2025).","journal-title":"Cell"},{"key":"76667_CR27","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/s41591-024-02894-y","volume":"30","author":"M Yarchoan","year":"2024","unstructured":"Yarchoan, M. et al. Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1\/2 trial. Nat. Med. 30, 1044\u20131053 (2024).","journal-title":"Nat. Med."},{"key":"76667_CR28","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1158\/1078-0432.CCR-23-3940","volume":"30","author":"AM D\u2019Alise","year":"2024","unstructured":"D\u2019Alise, A. M. et al. Phase I trial of viral vector-based personalized vaccination elicits robust neoantigen-specific antitumor T-cell responses. Clin. Cancer Res. 30, 2412\u20132423 (2024).","journal-title":"Clin. Cancer Res."},{"key":"76667_CR29","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber, J. S. et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet 403, 632\u2013644 (2024).","journal-title":"Lancet"},{"key":"76667_CR30","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1080\/21645515.2017.1334746","volume":"13","author":"K Bendjama","year":"2017","unstructured":"Bendjama, K. & Quemeneur, E. Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer. Hum. Vaccin. Immunother. 13, 1997\u20132003 (2017).","journal-title":"Hum. Vaccin. Immunother."},{"key":"76667_CR31","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.ccell.2021.04.014","volume":"39","author":"A Bagaev","year":"2021","unstructured":"Bagaev, A. et al. Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell 39, 845\u2013865.e7 (2021).","journal-title":"Cancer Cell"},{"key":"76667_CR32","doi-asserted-by":"publisher","first-page":"1226445","DOI":"10.3389\/fimmu.2023.1226445","volume":"14","author":"I Anzar","year":"2023","unstructured":"Anzar, I. et al. The interplay between neoantigens and immune cells in sarcomas treated with checkpoint inhibition. Front. Immunol. 14, 1226445 (2023).","journal-title":"Front. Immunol."},{"key":"76667_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmorw.2025.100581","volume":"10","author":"B Grellier","year":"2025","unstructured":"Grellier, B. et al. VacDesignR\u00ae: a computational tool to optimize viral-based individualized neoantigen therapeutic vaccine production. ESMO Real. World Data Digit. Oncol. 10, 100581 (2025).","journal-title":"ESMO Real. World Data Digit. Oncol."},{"key":"76667_CR34","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1016\/j.ccell.2023.11.005","volume":"41","author":"R Yossef","year":"2023","unstructured":"Yossef, R. et al. Phenotypic signatures of circulating neoantigen-reactive CD8+ T cells in patients with metastatic cancers. Cancer Cell 41, 2154\u20132165.e5 (2023).","journal-title":"Cancer Cell"},{"key":"76667_CR35","doi-asserted-by":"publisher","first-page":"113250","DOI":"10.1016\/j.celrep.2023.113250","volume":"42","author":"F Schmidt","year":"2023","unstructured":"Schmidt, F. et al. In-depth analysis of human virus-specific CD8+ T cells delineates unique phenotypic signatures for T cell specificity prediction. Cell Rep. 42, 113250 (2023).","journal-title":"Cell Rep."},{"key":"76667_CR36","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1126\/science.1208130","volume":"333","author":"N Stransky","year":"2011","unstructured":"Stransky, N. et al. The mutational landscape of head and neck squamous cell carcinoma. Science 333, 1157\u20131160 (2011).","journal-title":"Science"},{"key":"76667_CR37","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1053\/j.gastro.2014.03.007","volume":"147","author":"AM Di Bisceglie","year":"2014","unstructured":"Di Bisceglie, A. M. et al. Efficacy of immunotherapy with TG4040, peg-interferon, and ribavirin in a phase 2 study of patients with chronic HCV infection. Gastroenterology 147, 119\u2013131.e3 (2014).","journal-title":"Gastroenterology"},{"key":"76667_CR38","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/s41577-023-00853-1","volume":"23","author":"E Rotrosen","year":"2023","unstructured":"Rotrosen, E. & Kupper, T. S. Assessing the generation of tissue resident memory T cells by vaccines. Nat. Rev. Immunol. 23, 655\u2013665 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"76667_CR39","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1038\/nm917","volume":"9","author":"E Hammarlund","year":"2003","unstructured":"Hammarlund, E. et al. Duration of antiviral immunity after smallpox vaccination. Nat. Med. 9, 1131\u20131137 (2003).","journal-title":"Nat. Med."},{"key":"76667_CR40","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/BF01641272","volume":"3","author":"A Mayr","year":"1975","unstructured":"Mayr, A., Hochstein-Mintzel, V. & Stickl, H. Abstammung, eigenschaften und verwendung des attenuierten vaccinia-stammes MVA. Infection 3, 6\u201314 (1975).","journal-title":"Infection"},{"key":"76667_CR41","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1007\/s00262-010-0875-4","volume":"59","author":"Z Moodie","year":"2010","unstructured":"Moodie, Z. et al. Response definition criteria for ELISPOT assays revisited. Cancer Immunol. Immunother. 59, 1489\u20131501 (2010).","journal-title":"Cancer Immunol. Immunother."},{"key":"76667_CR42","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nbt.4096","volume":"36","author":"A Butler","year":"2018","unstructured":"Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411\u2013420 (2018).","journal-title":"Nat. Biotechnol."},{"key":"76667_CR43","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.1093\/bioinformatics\/btw339","volume":"32","author":"B Gerritsen","year":"2016","unstructured":"Gerritsen, B., Pandit, A., Andeweg, A. C. & de Boer, R. J. RTCR: a pipeline for complete and accurate recovery of T cell repertoires from high throughput sequencing data. Bioinformatics 32, 3098\u20133106 (2016).","journal-title":"Bioinformatics"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76667-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76667-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76667-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:04:04Z","timestamp":1789556644000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76667-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["76667"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-76667-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]},"assertion":[{"value":"22 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K. Bidet-Huang, B. Grellier, J. Deforges, M. Brandely, E. Qu\u00e9m\u00e9neur, B. Bastien, A. Tavernaro, G. Lacoste, V. Schoettel, C. Spring-Giusti, N. Silvestre, J.B Marchand, S. Robin, E. Dochy, M. Ceppi, A. Riva are employees or former employees of Transgene. N. Yamagata, P. Brattas, K. Onoguchi, Y. Yamashita, H. Fontenelle, M. Eggert Martinez, O. Baker are employees of NEC Bio. K. Bendjama was employed by Transgene, then NEC Bio. C. Le Tourneau has participated in advisory boards from MSD, J&J, GSK, Astra Zeneca, Transgene, LEO Pharma, BMS, DOB Pharmaceuticals, Bicara, Merus, Owkin, Genmab, Immutep, Roche, ALX Oncology, Merck Serono, Pfizer, Aveon, Seagen, MaxiVax, Kumar Therapeutics, PCI BioTech. J-P Delord has participated in advisory boards from BMS, Merck Serono, MSD, Pierre Fabre, Roche. C. Le Tourneau, C. Ottensmeier and O. Lantz received travel funding from Transgene to present the results of this study at international conferences. All other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"9863"}}